Anlotinib suppressed tumor cell proliferation via inhibition of platelet-derived growth factor receptors α/β (PDGFR α/β), c-Kit, Ret as well as Aurora-B, c-FMS, and discoidin domain receptor 1(DDR1), which was a group of newly identified kinase targets involving the tumor progression [14–17]. This evidence concerns the gene CSF1R and neoplasm.